Simon Kohl

Dr. Simon Kohl is the founder and CEO of Latent Labs, a frontier AI lab that enables biotech and pharmaceutical companies to generate and optimize proteins. Simon previously started and co-led DeepMind's protein design team and was a senior research scientist on the Nobel Prize-winning AlphaFold2 project, where he developed the crucial pLDDT confidence quantification system now widely used to predict laboratory success in protein design. At Latent Labs, backed by $50M in total funding from investors including Radical Ventures, Sofinnova Partners, Google Chief Scientist Jeff Dean and CEO of Anthropic Dario Amodei, Simon leads a team innovating frontier models that use cutting-edge generative techniques to computationally create new therapeutic molecules like antibodies and enzymes. The company is focused on enabling partners at scale to tackle challenging targets, develop precision medicines, and accelerate development timelines through their AI protein design platform.

Wednesday
May 07
Senior Leadership AIxBioPharma Luncheon - Inflection Points: Lessons from Computing and Cloud to Catalyze AI in Bio
12:15 PM

-

1:30 PM

This is an invite-only exclusive luncheon with senior leaders at the forefront of AI and BioPharma to explore how decades of progress in computational technologies can inform the next wave of breakthroughs in biology. Featuring insights from Sandy Pentland (MIT), Richard Socher (You.com, ex-Chief Scientist at Salesforce), Ola Wlodek (Constructive Bio), and Simon Kohl (Latent Labs) this conversation will examine the strategic parallels between past inflection points in computing and today’s rapidly evolving AI-driven biological revolution. From data infrastructure to predictive modeling and decision-making under uncertainty, what can we learn—and what must we do differently—as we chart the future of biology.

Other Speakers

Social Media

Other

Copyright SynBioBeta 2025

Social Media

Other

Copyright SynBioBeta 2025

Social Media

Other

Copyright SynBioBeta 2025